Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
复制标题
DOI：
10.1182/blood-2006-06-025627
复制
发表时间：
2007-05-01
期刊：
影响因子：
20.3
通讯作者：
Lowenberg, Bob
中科院分区：
文献类型：
--
作者：
Cornelissen, Jan J.;van Putten, Wim L. J.;Lowenberg, Bob
荷兰-比利时血液肿瘤学合作组和瑞士临床癌症研究组（HOVON-SAKK）合作研究组根据供体与非供体比较，评价了3项连续研究中首次缓解（CR 1）的急性髓性白血病（AML）患者（患者）的结局。在1987年至2004年期间，2287例患者入组这些研究，其中1032例（45%）无FAB M3或t（15;17）的患者在2个周期化疗后处于CR 1，接受巩固治疗，年龄小于55岁，因此有资格接受异基因造血干细胞移植（allo-SCT）。326名患者（32%）可获得HLA相同的兄弟姐妹捐赠者，而599名患者（58%）缺乏此类捐赠者，107名患者无法获得信息。allo-SCT的依从性为82%（268/326）。有供者和无供者的累积复发率分别为32%和59%（P
The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-donor comparison. Between 1987 and 2004, 2287 pts were entered in these studies of whom 1032 pts (45%) without FAB M3 or t(15;17) were in CR1 after 2 cycles of chemotherapy, received consolidation treatment, and were younger than 55 years of age and therefore eligible for allogeneic hematopoietic stem cell transplantation (allo-SCT). An HLA-identical sibling donor was available for 326 pts (32%), whereas 599 pts (58%) lacked such a donor, and information was not available in 107 pts. Compliance with allo-SCT was 82% (268 of 326). Cumulative incidences of relapse were, respectively, 32% versus 59% for pts with versus those without a donor (P